1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,200 | 7,500 | 10:02 | |
| 7,200 | 7,500 | 10:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs | 1 | GlobeNewswire (USA) | ||
| 11.03. | Why Is MiNK Therapeutics Stock Trading Lower On Wednesday? | 7 | Benzinga.com | ||
| 10.03. | MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally | 2 | Benzinga.com | ||
| 10.03. | Morning Market Movers: MiNK Therapeutics, Garden Stage, Arq, Inc., SciSparc See Big Swings | 456 | AFX News | BEIJING (dpa-AFX) - At 8:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 10.03. | MiNK Therapeutics rockets 60% after collaboration with C-Further for pediatric cancers | 6 | Seeking Alpha | ||
| 10.03. | MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers | 4 | GlobeNewswire (USA) | ||
| 04.02. | MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia | 1 | GlobeNewswire (USA) | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.01. | MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease | 326 | GlobeNewswire (Europe) | Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free... ► Artikel lesen | |
| 02.01. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.12.25 | MiNK Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 20.11.25 | MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors | 1 | GlobeNewswire (USA) | ||
| 14.11.25 | MiNK Therapeutics GAAP EPS of -$0.65 beats by $0.20 | 2 | Seeking Alpha | ||
| 14.11.25 | MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation | 263 | GlobeNewswire (Europe) | New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive... ► Artikel lesen | |
| 07.11.25 | MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 | 271 | GlobeNewswire (Europe) | Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune... ► Artikel lesen | |
| 05.11.25 | MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development | 3 | GlobeNewswire (USA) | ||
| 30.10.25 | MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting | 3 | GlobeNewswire (USA) | ||
| 29.09.25 | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09.25 | MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board | 2 | Investing.com | ||
| 29.09.25 | MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors | 11 | GlobeNewswire (USA) |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 75,90 | +0,93 % | Biotech-Werte im Check: Warum Emyria, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| BB BIOTECH | 46,900 | +0,43 % | EQS-News: BB BIOTECH AG: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.25 pro Aktie | EQS-News: BB BIOTECH AG
/ Schlagwort(e): Hauptversammlung/Dividende
Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.25... ► Artikel lesen | |
| OCUGEN | 1,666 | +0,54 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration |
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,230 | +1,15 % | Why Viking Therapeutics Stock Could Take Off Later This Year | ||
| EDITAS MEDICINE | 1,954 | +0,83 % | Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates | Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinical... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,435 | +0,88 % | Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies | ||
| GERON | 1,294 | -0,35 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EXACT SCIENCES | 90,94 | +0,22 % | XFRA EXK: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEXACT SCIEN. DL-... ► Artikel lesen | |
| BASILEA | 56,00 | -0,71 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea startet erste klinische Studie am Menschen für neuartiges Antibiotikum BAL2420 | Allschwil, 23. März 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| MICROBOT MEDICAL | 2,178 | -0,27 % | Microbot Medical study on robotic system published in peer-reviewed journal | ||
| TELIX PHARMACEUTICALS | 7,790 | +2,26 % | IBA SA: Telix selects IBA Cyclone KIUBE to support manufacturing expansion in the U.S. | Louvain-la-Neuve, Belgium- March 20, 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical... ► Artikel lesen | |
| REPLIGEN | 99,32 | -1,32 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year... ► Artikel lesen | |
| NOVOCURE | 9,842 | -1,40 % | NovoCure's Optune Lua Secures Japan Health Ministry's Reimbursement Approval For NSCLC Patients | WASHINGTON (dpa-AFX) - NovoCure Limited (NVCR), Monday announced that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua, authorized for use in adult patients... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,598 | -1,85 % | Jefferies reiterates Buy rating on CytomX stock after phase 1 data | ||
| UNIQURE | 12,980 | -1,03 % | uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease | LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen |
Das Unternehmen MINK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,150 (+2,04 %) liegt der Kurs bei 7,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.